Senju launches first-in-class dry eye disease drug in Japan

Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 antagonist class to reach the market.

Licensed from fellow Japanese drugmaker Mochida, Avarept (motugivatrep) ophthalmic suspension has been launched at a list price of JPY 577.50 ($3.63) per 5ml bottle and will be distributed in Japan by Takeda.

DED is a common inflammatory disorder estimated to affect over 20 million people in Japan and its incidence is rising with the country’s ageing population, long-term use of contact lenses, and excessive screen time. It is…